NCT03199027

Brief Summary

Following the announcement of the global "90-90-90" strategy, there is a huge need in South Africa for effective well-developed scaled-up models of ART (anti-retroviral therapy) delivery that aim to improve patient adherence and viral suppression. The ART adherence club is one such model of service delivery. The investigators are conducting a pragmatic randomised control trial to compare virological outcomes 12 months post-ART initiation between arms: individuals referred to the Adherence club at 4 months post-ART initiation (early referral) and individuals referred to the Adherence club at 12 months post-ART initiation (delayed referral). Individuals with delayed Adherence club referral will continue to attend the ART clinic as per the Standard-of-Care.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
220

participants targeted

Target at P50-P75 for not_applicable hiv

Timeline
Completed

Started Jan 2017

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 18, 2017

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

June 23, 2017

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 26, 2017

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 6, 2018

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 31, 2019

Completed
Last Updated

September 4, 2019

Status Verified

September 1, 2019

Enrollment Period

1.7 years

First QC Date

June 23, 2017

Last Update Submit

September 2, 2019

Conditions

Keywords

Adherence

Outcome Measures

Primary Outcomes (1)

  • Viral suppression

    Viral load \<400 copies/ml with secondary analyses at other thresholds

    Up to 12 months post-ART initiation

Secondary Outcomes (3)

  • Retention in care

    Up to 12 months post-ART initiation

  • Physical and Mental Health

    Up to 12 months post-ART initiation

  • Acceptability of the ART service

    Up to 12 months post-ART initiation

Study Arms (2)

Clinic-based Care

NO INTERVENTION

Clinic-based care is the current Standard-of-Care whereby newly initiated ART patients attend the ART clinic.

Adherence Club Care

EXPERIMENTAL

Adherence club care involves referral to community-based ART services in the form of Adherence clubs, which are led by community health workers and supported by ART clinic nurses.

Other: Adherence Club

Interventions

Participants will be referred to an Adherence Club at 4 months post-ART initiation. Adherence club visits occur 2-4 monthly at a community hall near the Community Health Centre (CHC). At routine visits, which last 1-2 hours, community health workers provide health education, weigh patients, ask about symptoms and dispense pre-packed ART. Symptomatic patients are sent back to the ART clinic for clinician assessment. An assigned nurse takes blood tests annually at each club, and then returns on the subsequent visit to perform a clinical assessment and check the results. Patients requiring more follow-up or with high viral loads are referred back to the ART clinic at the CHC by the nurse.

Adherence Club Care

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Documented HIV infection with ART initiation 4 months ago
  • Suppressed viral load at 4 months post-initiation (\<400 copies/ml)
  • All other month 4 blood results within normal limits
  • Willingness to be randomised and return for study measurement visits
  • Able to willing to attend service visits at either the clinic or a club
  • Able to provide informed consent for research

You may not qualify if:

  • Intention to relocate out of Cape Town permanently during the study period
  • Any medical, psychiatric or social condition which in the opinion of the investigators would affect the ability to consent and/or participate in the study
  • Pregnant
  • Current co-morbidity requiring additional health care, either acutely eg tuberculosis or chronically eg hypertension

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Gugulethu Community Health Centre

Cape Town, Western Cape, 7750, South Africa

Location

Related Publications (4)

  • Luque-Fernandez MA, Van Cutsem G, Goemaere E, Hilderbrand K, Schomaker M, Mantangana N, Mathee S, Dubula V, Ford N, Hernan MA, Boulle A. Effectiveness of patient adherence groups as a model of care for stable patients on antiretroviral therapy in Khayelitsha, Cape Town, South Africa. PLoS One. 2013;8(2):e56088. doi: 10.1371/journal.pone.0056088. Epub 2013 Feb 13.

    PMID: 23418518BACKGROUND
  • Grimsrud A, Sharp J, Kalombo C, Bekker LG, Myer L. Implementation of community-based adherence clubs for stable antiretroviral therapy patients in Cape Town, South Africa. J Int AIDS Soc. 2015 May 27;18(1):19984. doi: 10.7448/IAS.18.1.19984. eCollection 2015.

    PMID: 26022654BACKGROUND
  • Grimsrud A, Lesosky M, Kalombo C, Bekker LG, Myer L. Implementation and Operational Research: Community-Based Adherence Clubs for the Management of Stable Antiretroviral Therapy Patients in Cape Town, South Africa: A Cohort Study. J Acquir Immune Defic Syndr. 2016 Jan 1;71(1):e16-23. doi: 10.1097/QAI.0000000000000863.

    PMID: 26473798BACKGROUND
  • Takuva S, Brown AE, Pillay Y, Delpech V, Puren AJ. The continuum of HIV care in South Africa: implications for achieving the second and third UNAIDS 90-90-90 targets. AIDS. 2017 Feb 20;31(4):545-552. doi: 10.1097/QAD.0000000000001340.

    PMID: 28121668BACKGROUND

MeSH Terms

Conditions

Acquired Immunodeficiency Syndrome

Condition Hierarchy (Ancestors)

HIV InfectionsBlood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesSlow Virus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System Diseases

Study Officials

  • Landon Myer, MBChB PhD

    University of Cape Town

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

June 23, 2017

First Posted

June 26, 2017

Study Start

January 18, 2017

Primary Completion

October 6, 2018

Study Completion

January 31, 2019

Last Updated

September 4, 2019

Record last verified: 2019-09

Data Sharing

IPD Sharing
Will not share

Locations